Nasdaq · Biotech stocks database

HELP — Cybin Inc.

HELP (Cybin Inc.) stock: $12.37, $766.7M market cap, $157.3M cash, $609.4M EV, $638.7M fully diluted market cap. Next expected readout: Mar-27. Lead program: CYB003 (Major Depressive Disorder (MDD)), Phase 3. Data from Fully Diluted's biotech stocks database.

Share price

$12.37

Market cap

$766.7M

Cash

$157.3M

Enterprise value

$609.4M

Balance sheet

Cash	$157.3M
Debt	$0.0M
Net cash	$157.3M
Enterprise value	$609.4M
Basic shares	62.0M shares
Fully diluted shares	51.6M shares
Fully diluted market cap	$638.7M
Cash per share	$2.54

Cash figures as of 2026-03-31. Database snapshot: 2026-09-21.

Price history

Loading HELP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	CYB003	Phase 3	Major Depressive Disorder	—
Apr 29 - Jun 10	CYB003	Phase 3	Major Depressive Disorder (MDD); Depression in Adults; Depression - Major Depressive Disorder	—
Apr 26 - Jun 7	CYB003	Phase 3	Major Depressive Disorder	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	CYB003
Lead indication	Major Depressive Disorder (MDD)
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06793397	Phase 3	Recruiting	Sponsor	Cybin IRL Limited	—	Major Depressive Disorder (MDD); Depression in Adults; Depression - Major Depressive Disorder	—
NCT06605105	Phase 3	Enrolling by invitation	Sponsor	Cybin IRL Limited	—	Major Depressive Disorder	—
NCT06564818	Phase 3	Active, not recruiting	Sponsor	Cybin IRL Limited	—	Major Depressive Disorder	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Cybin IRL Limited on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	3,271,400	-561,443	0.41%	2026-08-14
Sphera Biotech	1,620,753	+633,663	1.53%	2026-08-14
Logos Global Management	750,000	+750,000	0.21%	2026-08-14
Ikarian Capital	132,153	no change	0.14%	2026-08-14
ADAR1 Capital Management	81,278	+50,000	0.03%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego